You are here

P&T News

November 3

A random set of patients could “test” drugs nearing an OK

November 2

Tighter prescribing, drug courts also recommended
Braeburn, Indivior recommended by large margins
Study results fail to justify continued development

October 31

New grant will allow ICER to evaluate all newly approved U.S. medicines
Forty-six states allege drug manufacturers restrained competition
Biologic reduced attacks and improved lung function across a broad population
Calquence demonstrated favorable overall response rate in initial studies
One in 10 naloxone-rescued OD patients die within a year

October 30

Inconsistent evidence prompts agency to re-evaluate link between soy products and cardiovascular health
Phase 3 study demonstrated 10-mg dose reduced risk of recurrent VTE by up to 74%
MM-121 is a fully human monoclonal antibody designed to block tumor survival signals
They also had significantly fewer new brain lesions versus those on interferon beta-1a
Subgroup analysis demonstrates improvement in patients who experienced at least one attack per week while on placebo

October 26

Vaccination now recommended starting at age 50
Duchenne muscular dystrophy drug fared poorly in trials
Rate of high total cholesterol falls from 18.3% to 12.4%
Medication helps prevent nausea and vomiting after chemotherapy
BioMarin Pharmaceutical is developing valoctocogene roxaparvovec

October 24

Agency not told of test alterations and customer complaints

Pages